Out of 33 evaluable patients with advanced ovarian cancer, resistant to extensive poly-chemotherapy, then treated with high-dose im medroxyprogesterone (MPA), five partial responses (15%) were obtained. No partial response was obtained in a comparable group of 30 patients treated with an oral schedule. Four patients (two po, 2 im) had stable disease for at least 3 months, and 16 experienced subjective improvement. Treatment was very well tolerated. This study shows that high-dose MPA has some activity in ovarian cancer, and is worthy of further investigation.

High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy / C. Mangioni, S. Franceschi, C. La Vecchia, M. D'Incalci. - In: GYNECOLOGIC ONCOLOGY. - ISSN 0090-8258. - 12:3(1981 Dec), pp. 314-318. [10.1016/0090-8258(81)90131-1]

High-dose medroxyprogesterone acetate (MPA) in advanced epithelial ovarian cancer resistant to first- or second-line chemotherapy

C. La Vecchia;
1981-12

Abstract

Out of 33 evaluable patients with advanced ovarian cancer, resistant to extensive poly-chemotherapy, then treated with high-dose im medroxyprogesterone (MPA), five partial responses (15%) were obtained. No partial response was obtained in a comparable group of 30 patients treated with an oral schedule. Four patients (two po, 2 im) had stable disease for at least 3 months, and 16 experienced subjective improvement. Treatment was very well tolerated. This study shows that high-dose MPA has some activity in ovarian cancer, and is worthy of further investigation.
Administration, Oral; Ovarian Neoplasms; Antineoplastic Agents; Delayed-Action Preparations; Humans; Injections, Intramuscular; Adult; Aged; Middle Aged; Medroxyprogesterone; Medroxyprogesterone Acetate; Female
Settore MED/01 - Statistica Medica
GYNECOLOGIC ONCOLOGY
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/184839
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 34
  • ???jsp.display-item.citation.isi??? 35
social impact